CureVac NV
NASDAQ:CVAC
CureVac NV
Research & Development
CureVac NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Research & Development
-€141.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Research & Development
-€2.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Research & Development
-€176m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Research & Development
-€56.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Research & Development
-€21.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Research & Development
-€15.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Research & Development?
Research & Development
-141.4m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Research & Development amounts to -141.4m EUR.
What is CureVac NV's Research & Development growth rate?
Research & Development CAGR 5Y
-27%
Over the last year, the Research & Development growth was -32%. The average annual Research & Development growth rates for CureVac NV have been 44% over the past three years , -27% over the past five years .
